Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Stryker's (SYK) Q3 earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.

Stryker (SYK) Q3 Earnings Meet Estimates, Revenues Beat

Here's how the medical-device giant met Wall Street Q3 revenue estimates and narrowly beat earnings expectations.

What's Behind Stryker's Solid Q3 Results

Stryker Corporation (SYK) CEO Kevin Lobo on Q3 2019 Results - Earnings Call Transcript

Stryker (SYK) delivered earnings and revenue surprises of 0.00% and 0.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Stryker (SYK) Q3 Earnings Match Estimates

Stryker stock slipped a small fraction late Tuesday after Stryker earnings of $1.91 per share on $3.59 billion in sales narrowly topped analysts' expectations for the third quarter.

This Medical Products Giant Just Narrowly Topped Third-Quarter Estimates

Kalamazoo, Michigan, Oct.  29, 2019  (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2019:

Stryker reports third quarter 2019 operating results

Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat third quarter 2019 view are likely to have contributed to Stryker's (SYK) Q3 earnings.

What's in the Offing for Stryker's (SYK) Earnings in Q3?

Is  (SYK) Outperforming Other Medical Stocks This Year?

Is Stryker (SYK) Outperforming Other Medical Stocks This Year?

Kalamazoo, Michigan, Oct.  21, 2019  (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today it has completed the acquisition of Mobius Imaging, LLC, a leader in point-of-care imaging technology, and its sister company, GYS Tech, LLC (DBA Cardan Robotics).

Stryker completes acquisition of Mobius Imaging and Cardan Robotics

This analysis of Stryker stock uses a 10-year time frame and assumes a recession will occur at some point over that period.

Stryker: A 10-Year, Full-Cycle Analysis

Stryker's (SYK) core Mako Platform has been consistently driving its top line.

Here's Why You Should Add Stryker (SYK) to Your Portfolio Now

Stryker's (SYK) broad product spectrum cushions the company from any significant sales shortfall.

Stryker Gains From Flagship Mako and Broad Product Spectrum

Accuray

Intuitive Surgical

Medtronic

Stereotaxis Inc

Varian Medical Systems

Accuray and Stereotaxis are hyper-focused on growth.

High-Tech Robotic Surgery Gets Specialized

The MedTech space is characterized by the presence of profitable (quasi)-oligopolies.

Stryker: Striking It Rich

Emerging market countries present lucrative prospects; consequently, investors can take a look at the space.

3 MedTech Stocks in Focus on Emerging Market Prospects

A number of MedTech companies are currently attempting to gain ground within the robotics-aided healthcare market.

The Rise of Robots in Surgery Puts Spotlight on These 3 Stocks

Orthofix International

In the near future, there is a probability of 3D-printed implantable organs becoming a reality, thereby increasing the number of lives saved.

3D Printing Gaining Popularity: 3 MedTech Stocks to Watch

Stryker (SYK) expects the buyout to remain neutral to its 2019 earnings.

Stryker's Mobius Imaging Buyout to Boost Its Spine Division

Kalamazoo, Michigan, Sept.  04, 2019  (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today a definitive agreement to acquire Mobius Imaging, LLC, a leader in point-of-care imaging technology, and its sister company, GYS Tech, LLC (DBA Cardan Robotics), in an all cash transaction of approximately $370 million upfront and up to $130 million of contingent payments associated with development and commercial milestones. The acquisition provides Stryker’s Spine division with immediate entry into the intra-operative imaging segment and aligns with Stryker’s implant and navigation offerings.

Stryker announces definitive agreement to acquire Mobius Imaging & Cardan Robotics

Biogen

CBRE Group

T. Rowe Price Group

ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

5 ROE Stocks to Profit as Trade War Flip-Flops Rattle Market

Stryker (SYK) reported earnings 30 days ago. What's next for the stock?

Stryker (SYK) Up 0.7% Since Last Earnings Report: Can It Continue?

Kalamazoo, Michigan, Aug.  21, 2019  (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) ) will participate in the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September 10, 2019 at the Grand Hyatt New York. 

Stryker to participate in Morgan Stanley 17th Annual Global Healthcare Conference

Stryker (SYK) gains from core segments in the second quarter of 2019.

Here's Why You Should Add Stryker (SYK) to Your Portfolio

President and COO of Stryker Corp (30-Year Financial, Insider Trades) Timothy J Scannell (insider trades) sold 4,666 shares of SYK on 08/16/2019 at an average price of $217.08 a share.

Stryker Corp (SYK) President and COO Timothy J Scannell Sold $1 million of Shares

Abbott Labs

Baxter

Becton, Dickinson and Co.

Boston Scientific

Edwards Lifesciences

Illumina

Johnson & Johnson

Market caps for these medical device stocks are big. Most of them have been big winners, too.

News for Stryker Stock (SYK)